Osteosarcomas: Treatment Strategies, 2nd Edition
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 24
Special Issue Editor
Interests: natural compounds; chemical genomics; functional foods; cosmeceuticals; cancer biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Osteosarcoma, also known as bone tumor, generally affects children and adolescents. According to the latest cancer statistics, osteosarcoma was ranked as having the lowest five-year relative survival rate among the most common childhood and adolescent cancers in the USA. Since modern therapeutic methods have developed rapidly, the outcome for patients with osteosarcoma has improved. Typical treatments for osteosarcoma include surgery and intensive chemotherapy. However, with respect to recurrent and metastatic osteosarcoma, the existing treatments, including surgery and chemotherapy, exhibit a limited therapeutic effect. Therefore, it is necessary to develop new therapeutic strategies to treat osteosarcoma.
Pharmaceuticals invites both original research articles and reviews that shed light on the recent challenges in developing therapeutic strategies for the treatment of osteosarcoma. Topics of interest include drug development, drug repositioning, selective optimization of lead compounds, and drug combinations. The collection of manuscripts will be published as a Special Issue of the journal.
Dr. See-Hyoung Park
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- osteosarcoma
- anti-cancer
- apoptosis
- natural compounds
- target
- drug
Related Special Issue
- Osteosarcomas: Treatment Strategies in Pharmaceuticals (9 articles)
